CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CTMX - CytomX Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.50
DETAILS
HIGH:
$11.00
LOW:
$6.00
MEDIAN:
$8.50
CONSENSUS:
$8.50
UPSIDE:
232.03%
Stock News
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Varseta-M for the treatment of patients with relapsed/refractory metastatic colorectal cancer.
AWM Investment Company Inc. Acquires Shares of 150,000 CytomX Therapeutics, Inc. $CTMX
AWM Investment Company Inc. acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ: CTMX) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor acquired 150,000 shares of the biotechnology company's stock, valued at approximately $562,000. AWM Investment Company Inc. owned 0.07% of CytomX Therapeutics at the
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX
Bank of America Corp DE boosted its position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 1,064.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,202,785 shares of the biotechnology company's stock after purchasing an additional 9,326,480 shares during the quarter. Bank
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limiting drug activity in healthy tissue. Their lead asset is Varseta-M, which has interesting early colorectal cancer activity. Yet, it still requires larger and more mature datasets. CTMX's pipeline has lined up a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts. These are several catalysts through 1H2027.
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics NASDAQ: CTMX said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers.
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to break-even earnings per share a year ago.
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing.
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Alejandra Carvajal as Chief Legal Officer.
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report second quarter financial results on Thursday, August 6, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
ADAR1 Capital Management LLC Sells 872,579 Shares of CytomX Therapeutics, Inc. $CTMX
ADAR1 Capital Management LLC reduced its position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 20.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,410,190 shares of the biotechnology company's stock after selling 872,579 shares during the quarter. CytomX
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors.
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY ® and Regeneron's Veloci-Bi ® platforms -
CytomX Therapeutics: Cashed Up With Catalysts Ahead
In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, extending its cash runway and enabling broader Varseta-M development. CTMX's cash position of $346.7M supports operations into at least H2'28, with anticipated increased R&D spending as programs expand.
CytomX Therapeutics to Present at Upcoming June Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in June.
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata Gokhale, Ph.D.
Price Targets
CytomX Therapeutics initiated with an Outperform at Wolfe Research
$6.00
(was $3.50)
Wolfe Research
CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright
$11.00
(was $3.98)
H.C. Wainwright
CytomX Therapeutics (CTMX) PT Raised to $16 at Jefferies: 'buying opportunity here'
$16.00
(was $4.61)
Roger Song
·
Jefferies
CytomX Therapeutics (CTMX) PT Raised to $12 at Oppenheimer
$12.00
(was $8.03)
Matthew Biegler
·
Oppenheimer
CytomX Therapeutics price target raised to $10 from $8 at Barclays
$10.00
(was $6.07)
Barclays
CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler
$10.00
(was $5.39)
Piper Sandler
CytomX Therapeutics initiated with a Buy at Guggenheim
$10.00
(was $5.39)
Michael Schmidt
·
Guggenheim
CytomX Therapeutics price target raised to $8 from $6 at Barclays
$8.00
(was $5.39)
Etzer Darout
·
Barclays
CytomX Therapeutics price target raised to $6 from $3.50 at Barclays
$6.00
(was $3.74)
Etzer Darout
·
Barclays
CytomX Therapeutics assumed with an Overweight at Barclays
$3.50
(was $1.96)
Etzer Darout
·
Barclays
CytomX Therapeutics initiated with an Outperform at Oppenheimer
$7.00
(was $2.32)
Matthew Biegler
·
Oppenheimer
CytomX Therapeutics (CTMX) PT Raised to $3.68 at BMO Capital
$3.68
(was $1.09)
Etzer Darout
·
BMO Capital
CytomX Therapeutics (CTMX) PT Lowered to $3.25 at Piper Sandler
$3.25
(was $1.09)
Joseph Catanzaro
·
Piper Sandler
CytomX Therapeutics (CTMX) PT Lowered to $3.56 at BMO Capital
$3.56
(was $1.18)
Etzer Darout
·
BMO Capital
CytomX Therapeutics upgraded to Overweight from Neutral at Piper Sandler
$3.50
(was $1.75)
Joseph Catanzaro
·
Piper Sandler
CytomX Therapeutics (CTMX) PT Raised to $3.59 at BMO Capital
$3.59
(was $4.19)
Etzer Darout
·
BMO Capital
Wedbush Upgrades CytomX Therapeutics (CTMX) to Outperform
$8.00
(was $2.40)
Robert Driscoll
·
Wedbush
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
$8.00
(was $4.46)
Roger Song
·
Jefferies
CytomX Therapeutics (CTMX) PT Raised to $2.50 at Jefferies, 'EGFRxCD3 on Track for Ph1a Data in 2H24'
$2.50
(was $2.15)
Roger Song
·
Jefferies
CytomX Therapeutics (CTMX) PT Lowered to $3.25 at BMO Capital, 'Pipeline Updates Broadly in Line'
$3.25
(was $2.15)
Etzer Darout
·
BMO Capital